Literature DB >> 10999347

Analysis of biofluids for gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) by headspace GC-FID and GC-MS.

M A LeBeau1, M A Montgomery, M L Miller, S G Burmeister.   

Abstract

The past few years have seen a dramatic increase in the abuse of gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) in the United States. The abuse stems primarily from their euphoric and sedative properties, but these substances are also misused by bodybuilders as steroid alternatives. Recently there has been an alarming increase in the use of GHB and GBL in crimes of drug-facilitated sexual assault. A rapid and sensitive procedure was developed for the analysis of biofluids containing GHB and GBL. Two separate aliquots of a biological specimen were spiked with an alpha-methylene-gamma-butyrolactone internal standard solution. One of the aliquots was treated with concentrated sulfuric acid for cyclization of GHB to GBL and the other remained untreated. Both aliquots were extracted with methylene chloride and concentrated. Extracts were screened using automated headspace gas chromatography-flame-ionization detection (GC-FID). Qualitative findings were quantitated and confirmed in a manner similar to the GC-FID procedure with some modifications. A calibrated solution of GHB-d6 (or GBL-d6, when warranted) was added to the aliquots at a concentration approximating the level determined by the GC-FID screen. The extraction was as described with conversion of GHB to GBL, but analysis was by full-scan gas chromatography-mass spectrometry (El). Quantitation was performed by comparison of the area of the molecular ion of the parent drug (m/z 86) to that of the calibrated deuterated analogue (m/z 92). This analytical procedure allows for the rapid detection of GHB and GBL in biofluids. Its sensitivity has proven useful for the toxicological investigation of cases of drug-facilitated sexual assault.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999347     DOI: 10.1093/jat/24.6.421

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  7 in total

Review 1.  Street drug abuse leading to critical illness.

Authors:  Babak Mokhlesi; Prasad S Garimella; Aaron Joffe; Valerie Velho
Journal:  Intensive Care Med       Date:  2004-03-04       Impact factor: 17.440

2.  GHB urine concentrations after single-dose administration in humans.

Authors:  Christine Haller; Dung Thai; Peyton Jacob; Jo Ellen Dyer
Journal:  J Anal Toxicol       Date:  2006 Jul-Aug       Impact factor: 3.367

3.  Chemical and olfactory characterization of odorous compounds and their precursors in the parotoid gland secretion of the green tree frog, Litoria caerulea.

Authors:  Benjamin P C Smith; Michael J Tyler; Brian D Williams; Yoji Hayasaka
Journal:  J Chem Ecol       Date:  2003-09       Impact factor: 2.626

Review 4.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

5.  Targeted screening of succinic semialdehyde dehydrogenase deficiency (SSADHD) employing an enzymatic assay for γ-hydroxybutyric acid (GHB) in biofluids.

Authors:  C Wernli; S Finochiaro; C Volken; H Andresen-Streichert; A Buettler; D Gygax; G S Salomons; E E Jansen; G R Ainslie; K R Vogel; K M Gibson
Journal:  Mol Genet Metab Rep       Date:  2016-08-17

6.  Smartphone-based colorimetric determination of gamma-butyrolactone and gamma-hydroxybutyrate in alcoholic beverage samples.

Authors:  Anselmo Procida; Kevin C Honeychurch
Journal:  J Forensic Sci       Date:  2022-04-03       Impact factor: 1.717

7.  Repurposing of substances with lactone moiety for the treatment of γ-Hydroxybutyric acid and γ-Butyrolactone intoxication through modulating paraoxonase and PPARγ.

Authors:  Sepand Tehrani Fateh; Amir Salehi-Najafabadi
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.